MUST SEE: Replicel

About RepliCel RepliCel Life Sciences is developing an autologous cell-based procedure for the treatment of androgenetic alopecia (pattern baldness) and general hair loss in men and women. Efforts are now focused on ensuring the safety and demonstrating the efficacy of RepliCel’s cell-based hair regeneration procedure in humans. The long-term goal is the development of a safe, evidence-based, minimally invasive procedure to treat various types of hair loss in men and women. Breakthrough Findings RepliCel Life Sciences was founded to advance the breakthrough findings of Dr. Kevin McElwee and Dr. Rolf Hoffmann, established research scientists in the fields of immunology, hair biology, hair growth, and dermatology. In the early 2000s, at Phillips University in Marburg, Germany, Drs. McElwee and Hoffmann discovered that dermal sheath cup cells have the ability to initiate cellular growth of mature hair follicles in animals. RepliCel is now developing this discovery as a potential treatment for hair loss in humans. In addition to the discovery of the critical cell population, RepliCel has created a proprietary method for extracting and, replicating dermal sheath cup cells, with the goal of developing a safe minimally invasive procedure for inducing natural hair growth in men and women suffering from various types of hair loss. The procedure has shown promise in pre-clinical trials, based on tissue engineering and laboratory models. The procedure is now undergoing further rigorous study to establish safety and determine effectiveness. The first human clinical trial (Phase I/IIa) began in the country of Georgia in December 2010. On May 2, 2012, the Company announced positive results from its interim analysis of six-month data. Visit http://www.replicel.com/replicel-releases-positive-results-from-the-interim-analysis-of-data-from-its-first-in-man-ts001-2009-clinical-trial/ to learn more. All results from this interim analysis will be incorporated into the regulatory filings being developed for the initiation of a Phase IIb dose ranging trial expected to commence in late 2012 in European and/or North America. http://www.replicel.com/about/corporate-overview/